CVS · NYSE · STOCK
CVS Health (CVS) Stock Analysis
$86.18
52W $69.51 – $110.68
58/100
$109.93B
22.5
0.60
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is CVS Bullish or Bearish?
Bullish.
Innellis AI committee rates CVS Health (CVS) Buy with a composite score of 58/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +17.18 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -2.82 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Value Analyst sees a compelling case — price-to-book of 1.3x is a discount to asset value. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- Dividend yield of 3.5% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Current ratio of 0.84 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
58/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 46%
of 192 Healthcare peers
Value Analyst
bullish
70
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.3x is a discount to asset value
Growth Analyst
neutral
52
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.84 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 84 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score weakened from 61.8 to 57.8.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Analyst(s) changed stance: Risk Analyst.
Analyst-level changes:
- News Analyst: score 70->64 (-6); +1 bullish signal(s).
- Risk Analyst: stance neutral->bearish; score 52->35 (-18).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
39.7
Neutral
MACD Histogram
0.287
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Mixed
Support
$81.82
Resistance
$87.78
Bollinger %B
0.33
Inside Bands
Price vs Moving Averages
EMA 9
$87.07
Below
EMA 21
$88.65
Below
EMA 50
$92.00
Below
EMA 200
$88.75
Below
Fundamental Analysis
Valuation
57
Growth
75
Profitability
6
Financial Health
41
Cash Flow
70
Valuation
P/E Ratio
22.5×
P/B Ratio
1.38×
PEG Ratio
3.52
Dividend Yield
3.09%
52W High
$110.68
52W Low
$69.51
Quality & Growth
ROE
235.1%
ROA
67.7%
Gross Margin
1415.3%
Operating Margin
199.7%
Revenue Growth YoY
—
Debt / Equity
0.96
AI Fundamental Assessment
P/E ratio of 22.5 (inexpensive relative to a 15-40x range); Price-to-book of 1.4x; PEG ratio of 3.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.4%; Return on assets of 0.7%; Net margin of 1.2%; Gross margin of 14.2%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 0.96; Free cash flow per share is positive (9.21); Most recent quarter beat estimates by 38.0%; 5 consecutive earnings beats; EPS growth decelerating (+135.8% -> +0.4% QoQ); Average YoY EPS growth of 42.5%; Analyst estimates rising over recent quarters
Get the Full CVS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →